CN115677737A - 一种有潜在抗肿瘤作用的稀土配合物及其制备方法 - Google Patents
一种有潜在抗肿瘤作用的稀土配合物及其制备方法 Download PDFInfo
- Publication number
- CN115677737A CN115677737A CN202211309493.8A CN202211309493A CN115677737A CN 115677737 A CN115677737 A CN 115677737A CN 202211309493 A CN202211309493 A CN 202211309493A CN 115677737 A CN115677737 A CN 115677737A
- Authority
- CN
- China
- Prior art keywords
- complex
- rare earth
- dmf
- pyridine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052761 rare earth metal Inorganic materials 0.000 title claims abstract description 33
- 150000002910 rare earth metals Chemical class 0.000 title claims abstract description 26
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 30
- -1 rare earth metal ions Chemical class 0.000 claims abstract description 19
- 239000003446 ligand Substances 0.000 claims abstract description 11
- 238000001027 hydrothermal synthesis Methods 0.000 claims abstract description 7
- 239000011521 glass Substances 0.000 claims abstract description 5
- GJKFIJKSBFYMQK-UHFFFAOYSA-N lanthanum(3+);trinitrate;hexahydrate Chemical compound O.O.O.O.O.O.[La+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O GJKFIJKSBFYMQK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000012046 mixed solvent Substances 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 3
- 229910052746 lanthanum Inorganic materials 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 16
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract description 8
- XZBIXDPGRMLSTC-UHFFFAOYSA-N formohydrazide Chemical compound NNC=O XZBIXDPGRMLSTC-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002262 Schiff base Substances 0.000 description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
- 229960005542 ethidium bromide Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005536 corrosion prevention Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- CZMAIROVPAYCMU-UHFFFAOYSA-N lanthanum(3+) Chemical compound [La+3] CZMAIROVPAYCMU-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Pyridine Compounds (AREA)
Abstract
本发明公开了一种具有抗肿瘤作用的稀土金属配合物,涉及一种抗肿瘤配合物及其制备方法,采用2,6‑双[(2‑吡啶亚甲基)甲酰肼]吡啶为配体,稀土金属离子La(III)为配位原子,通过改变各物质的摩尔比,以水热法为合成技术,制得一种新颖的稀土配合物[La3(L)2(NO3)5(DMF)2]。制备步骤为:将配体2,6‑双[(2‑吡啶亚甲基)甲酰肼]吡啶和六水合硝酸镧按1:3的比例加入到18 mL DMF/MeOH混合溶剂(v/v=1:5)中,搅拌1小时;将悬液转移到20 ml玻璃瓶中,60℃保存3天,室温下自然冷却,得到的产物用甲醇洗涤并过滤。本发明为该配合物后续作为抗肿瘤新药奠定了基础,为发现抗肿瘤新药物提供重要的科学依据。
Description
技术领域
本发明涉及一种抗肿瘤配合物及其制备方法,特别是涉及一种有潜在抗肿瘤作用的稀土配合物及其制备方法。
背景技术
研究表明,稀土离子本身具有独特的生理、生物活性,而且还有很好的消炎、抗凝血、镇痛作用,尤其在抑菌、抗病毒、抗肿瘤等方面有着很好的效果。稀土离子由于其结构及物理化学性质的特点,可以和许多无机或有机配体形成配合物,而合成的配合物不仅可以降低稀土的毒性,增强其抗肿瘤作用,而且还能增加稀土的脂/水溶性,且药物的溶解度是影响药物在生物体内吸收的关键因素之一。很多研究表明稀土配合物有良好的抗肿瘤活性,其中一些表现出不同于铂类药物的抗肿瘤机制,可以克服对铂类药物的交叉耐药性。
自席夫碱被发现以来,即有大量研究表明席夫碱及其配合物具有多种活性,在生物医学方面,具有杀虫、抑菌、抗病毒、抗肿瘤等生物活性;在分析化学、功能材料、防腐蚀等多方面领域具有重要应用。尤其是对多种肿瘤细胞具有显著的抑制作用,且与金属离子形成配合物后其抗肿瘤作用有所增强。在这一背景下,基于发现一种新型的希夫碱类稀土金属配合物表现出优于顺铂的交叉耐药性和第一溶解性。
发明内容
本发明的目的在于提供一种有潜在抗肿瘤作用的稀土配合物及其制备方法,本发明提出稀土金属配合物[La3(L)2(NO3)5 (DMF)2]及其制备方法和条件,采用具有刚性结构的含氮的有机化合物2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶为配体,通过调节各物质摩尔比,以水热合成技术制备;采用配合物与EtBr-DNA竞争实验验证了该配合物与DNA有一定的结合能力,证明本发明具有抗肿瘤作用。
本发明的目的是通过以下技术方案实现的:
一种有潜在抗肿瘤作用的稀土配合物,该配合物[La3(L)2(NO3)5 (DMF)2]的配位结构图是:
所述的一种有潜在抗肿瘤作用的稀土配合物,该配合物的镧离子通过有机配合物而连接形成螺旋线性单体配合物。
一种有潜在抗肿瘤作用的稀土配合物的制备方法,所述配合物于水热反应生长方式;
制备步骤为:将配体2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶和六水合硝酸镧按1:3的比例加入到18 mL DMF/MeOH混合溶剂(v/v=1:5)中,搅拌1小时;将悬液转移到20 ml玻璃瓶中,60℃保存3天,室温下自然冷却,得到的产物用甲醇洗涤并过滤。
本发明的优点与效果是:
1. X射线衍射测试结果表明,该配合物[La3(L)2(NO3)5 (DMF)2]组成和结构明确。
2. 本发明采用稀土金属镧离子作为中心离子,本身具有独特的生理、生物活性,且与配体形成配合物后不仅可降低金属的毒性,增强抗肿瘤活性,还能增强其水溶性。
3. 本发明采用希夫碱类化合物2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶作为配体,对多种肿瘤细胞具有显著的抑制作用,且与金属离子形成配合物后其抗肿瘤作用有所增强。
4. 本发明采用同时具有抗肿瘤活性的稀土金属镧离子和希夫碱化合物形成配合物,得到一种具有潜在抗肿瘤作用的新型稀土配合物,具有一定的开发价值。
5. 本发明采用荧光光谱实验结果说明了本发明与DNA有一定的结合能力,证明本发明作为一种具有抗肿瘤作用的新型稀土配合物有开发价值。
附图说明
图1为本发明配合物[La3(L)2(NO3)5 (DMF)2]的配位结构图;
图2为本发明配合物与EtBr-DNA竞争实验的荧光发射图。
具体实施方式
下面结合附图所示实施例对本发明进行详细说明。
本发明稀土金属配合物[La3(L)2(NO3)5 (DMF)2]的分子结构为:螺旋线性三核单体配合物
一种新型稀土金属配合物[La3(L)2(NO3)5 (DMF)2]的制备方法,起制备步骤为:将六水合硝酸镧以甲醇溶解作为体系一,配体2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶以DMF溶解为体系二,将两体系混合,于室温下搅拌约60分钟,然后把混合物转移到20 ml水热反应玻璃瓶中,在60℃恒温72小时,降温直到室温,所得黄色晶体,用甲醇洗涤,得到产物[La3(L)2(NO3)5 (DMF)2]。
所述的稀土金属配合物的制备方法,其采用2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶为配体,镧离子为配位原子。
本发明采用荧光光谱法进行了配合物与EtBr-DNA竞争实验,研究了该配合物与DNA的相互结合作用,实验方法如下:将DNA溶液和溴化乙锭水溶液混合与于烧杯中,避光静置两个小时后加入配合物溶液,配合物溶液的加入体积梯度为0-7mL,最终将溶液用Tris–HCl缓冲溶液定容到20mL,得到一系列浓度梯度的待检测样品溶液后为使配合物与EtBr-DNA溶液充分反应,继续避光放置。2小时后上机检测。狭缝宽度均设为10nm,根据检测到的激发波长(526nm)和发射波长(618nm),在540~760nm范围内扫描待测样品溶液的发射光谱并记录数据。
下面结合附图所示实施例予以说明:
本发明明确了其分子[La3(L)2(NO3)5 (DMF)2]的空间结构;通过2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶为配体,镧离子为配位原子,改变各物质的摩尔比,以水热法为合成技术,制备一种稀土配合物。将六水合硝酸镧(130.0 mg,0.3 mmol)和配体2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶(37.3mg,0.1 mmol)溶解于DMF/MeOH混合溶剂(v/v=1:5 ,18 mL)中,于室温下搅拌约60分钟,然后把混合物转移到20 ml水热反应玻璃瓶中,在60℃恒温72小时,降温直到室温,所得黄色晶体,用甲醇洗涤,得到产物[La3(L)2(NO3)5 (DMF)2]。
X射线衍射测试结果表明,该配合物[La3(L)2(NO3)5 (DMF)2]组成和结构明确。
本发明采用荧光光谱法进行了配合物与EtBr-DNA竞争实验,研究了该配合物与DNA的相互结合作用,实验方法如下:将准确称取的6.006g 粉末状Tris和2.925g 粉末状NaCl搅拌至充分溶解,并使用蒸馏水定容在恒定体积为500mL的容量瓶中,等待备用。将4.17mL浓盐酸(12mol/L)缓慢滴入蒸馏水中,滴入过程中不断搅拌,并使用蒸馏水稀释至恒定体积500mL。将上述500mL Tris-NaCl溶液与420mL稀HCl溶液混合摇匀后,使用蒸馏水定容至最终体积1000mL,形成Tris-HCl(pH=7.2)缓冲液。精确称量0.0026g小牛胸腺DNA并溶解在适量的蒸馏水,待其充分溶解后,定容至恒定体积为100mL的容量瓶中并搅拌一小时。从装有浓度为1mmol/L 溴化乙锭溶液的试剂瓶中取出1mL,溶于9mL的蒸馏水中,溶解均匀后将其放置于温度设置为4℃的冰箱中备用。在没有强亮光的条件下,分别称量取1mL小牛胸腺DNA溶液和0.4mL溴化乙锭溶液,将其均匀混合,避光反应进行两小时,以形成EtBr-DNA溶液,然后加入不同体积的配合物溶液,最后使用Tris-HCl缓冲液将所有待测量的混合溶液都定容至20mL,形成一系列具有不同浓度梯度的混合溶液,再避光反应两小时后,上荧光光谱仪进行测试。荧光光谱仪激发与发射的狭缝宽度参数均设置为6nm,设置激发波长λex为526nm,以800nm/min的扫描速度检测波长为540~760nm的反应混合待测溶液发射光谱图。
配合物与EtBr-DNA竞争实验荧光发射图谱显示,随着配合物浓度的增加,DNA-EB系统的荧光强度显着降低,表明配合物与DNA结合后,较大一部分EB分子被释放到溶液中,配合物与EB的交换导致荧光猝灭。结果表明配合物[La3(L)2(NO3)5 (DMF)2]可与DNA相结合从而影响DNA的转录,抑制肿瘤细胞。
Claims (3)
2.根据权利要求1所述的一种有潜在抗肿瘤作用的稀土配合物,其特征在于,该配合物的镧离子通过有机配合物而连接形成螺旋线性单体配合物。
3.一种有潜在抗肿瘤作用的稀土配合物的制备方法,其特征在于,所述配合物于水热反应生长方式;
制备步骤为:将配体2,6-双[(2-吡啶亚甲基)甲酰肼]吡啶和六水合硝酸镧按1:3的比例加入到18 mL DMF/MeOH混合溶剂(v/v=1:5)中,搅拌1小时;将悬液转移到20 ml玻璃瓶中,60℃保存3天,室温下自然冷却,得到的产物用甲醇洗涤并过滤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211309493.8A CN115677737A (zh) | 2022-10-25 | 2022-10-25 | 一种有潜在抗肿瘤作用的稀土配合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211309493.8A CN115677737A (zh) | 2022-10-25 | 2022-10-25 | 一种有潜在抗肿瘤作用的稀土配合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115677737A true CN115677737A (zh) | 2023-02-03 |
Family
ID=85099032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211309493.8A Pending CN115677737A (zh) | 2022-10-25 | 2022-10-25 | 一种有潜在抗肿瘤作用的稀土配合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115677737A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012489A (zh) * | 2011-09-22 | 2013-04-03 | 中国石油化工股份有限公司 | 2-乙酰基吡啶缩苯甲酰肼钼络合物及其制备方法 |
WO2016058066A1 (pt) * | 2014-10-15 | 2016-04-21 | Universidade Estadual De Campinas - Unicamp | Complexo lantanídeo-ligantes; processo de obtenção dos complexos lantanídeo-ligantes; ligantes derivados do ácido dipicolínico; e, uso dos complexos lantanídeo-ligantes |
CN105777783A (zh) * | 2016-02-25 | 2016-07-20 | 聊城大学 | (2-吡啶甲醛)-2,6吡啶双酰腙铜化合物、制备方法及其应用 |
CN106432304A (zh) * | 2016-09-13 | 2017-02-22 | 桂林理工大学 | 配合物[La(L1)(HL1)(H2O)(NO3)2]及制备抗癌药物应用 |
CN106432303A (zh) * | 2016-09-13 | 2017-02-22 | 桂林理工大学 | 配合物[Ce(L1)2(H2O)(NO3)2]及制备抗癌药物应用 |
WO2020068015A1 (en) * | 2018-09-26 | 2020-04-02 | Karadeniz Teknik Universitesi | Water-soluble, non-aggregated silicon phtalgcyanine compound having in vitro anticancer effect against cancer types of lung, liver, brest and melanoma |
-
2022
- 2022-10-25 CN CN202211309493.8A patent/CN115677737A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012489A (zh) * | 2011-09-22 | 2013-04-03 | 中国石油化工股份有限公司 | 2-乙酰基吡啶缩苯甲酰肼钼络合物及其制备方法 |
WO2016058066A1 (pt) * | 2014-10-15 | 2016-04-21 | Universidade Estadual De Campinas - Unicamp | Complexo lantanídeo-ligantes; processo de obtenção dos complexos lantanídeo-ligantes; ligantes derivados do ácido dipicolínico; e, uso dos complexos lantanídeo-ligantes |
CN105777783A (zh) * | 2016-02-25 | 2016-07-20 | 聊城大学 | (2-吡啶甲醛)-2,6吡啶双酰腙铜化合物、制备方法及其应用 |
CN106432304A (zh) * | 2016-09-13 | 2017-02-22 | 桂林理工大学 | 配合物[La(L1)(HL1)(H2O)(NO3)2]及制备抗癌药物应用 |
CN106432303A (zh) * | 2016-09-13 | 2017-02-22 | 桂林理工大学 | 配合物[Ce(L1)2(H2O)(NO3)2]及制备抗癌药物应用 |
WO2020068015A1 (en) * | 2018-09-26 | 2020-04-02 | Karadeniz Teknik Universitesi | Water-soluble, non-aggregated silicon phtalgcyanine compound having in vitro anticancer effect against cancer types of lung, liver, brest and melanoma |
Non-Patent Citations (1)
Title |
---|
AMITADHIKARY等,: "Synthesis, crystal structure, magnetic study and magneto-structural correlation of three Cu(II) complexes formed via pyridine bis(hydrazone) based ligand", RSC ADV., 20 January 2014 (2014-01-20), pages 12408 - 12414 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kitchen et al. | Circularly polarized lanthanide luminescence from Langmuir-Blodgett films formed from optically active and amphiphilic Eu (III) based self-assembly complexes | |
Evans et al. | Advances in anion supramolecular chemistry: from recognition to chemical applications | |
Glasson et al. | Recent developments in the d-block metallo-supramolecular chemistry of polypyridyls | |
Tabassum et al. | Synthesis of heterobimetallic complexes: In vitro DNA binding, cleavage and antimicrobial studies | |
Shahabadi et al. | Identification of binding mode of a platinum (II) complex, PtCl2 (DIP), and calf thymus DNA | |
Domracheva et al. | Iron‐Containing Poly (propylene imine) Dendromesogens with Photoactive Properties | |
Keshavarzian et al. | Heterodinuclear Cu–Gd (3d-4f) complex with di-compartmental Schiff base ligand in biological activity: Synthesis, crystal structure, catecholase activity and DNA & BSA-binding studies | |
Njogu et al. | Synthesis, characterization, antimicrobial screening and DNA binding of novel silver (I)–thienylterpyridine and silver (I)–furylterpyridine complexes | |
Ji et al. | A robust turn-on luminescent MOF probe with redox center and rare RE4 cluster for highly sensitive detection of captopril | |
Chandra et al. | Coordination mode of pentadentate ligand derivative of 5-amino-1, 3, 4-thiadiazole-2-thiol with nickel (II) and copper (II) metal ions: synthesis, spectroscopic characterization, molecular modeling and fungicidal study | |
Kumar et al. | Exploration of synthesis, structural aspects, DFT studies and bio-efficacy of some new DHA-benzohydrazide based copper (II) complexes | |
Bhowmik et al. | Anion directed templated synthesis of mono-and di-condensed Schiff base compounds of Cu (II) | |
Ostrowska et al. | Explaining how α-hydroxamate ligands control the formation of Cu (II)-, Ni (II)-, and Zn (II)-containing metallacrowns | |
Jia et al. | Host–guest inclusion systems of nedaplatin with cucurbit [7] uril for improved in vitro antitumour activity | |
Suijkerbuijk et al. | Synthesis of and evidence for electronic communication within Heteromultimetallic Tetrakis (NCN-pincer metal)−(metallo) porphyrin hybrids | |
Wang et al. | Nickel chloride complexes with substituted 4′-phenyl-2′, 2′: 6′, 2 ″-terpyridine ligands: synthesis, characterization, anti-proliferation activity and biomolecule interactions | |
Omar et al. | Synthesis, spectral, thermal, potentiometric, antitumor, antimicrobial and PM3 studies of pyridazinone hydrazone metal complexes | |
Liang et al. | A novel triazene-based cadmium metal–organic framework as a selective fluorescent sensor for Hg2+ | |
Cucos et al. | Cobalt (II) ions connecting [CoII4] helicates into a 2-D coordination polymer showing slow relaxation of the magnetization | |
Wang et al. | Crystal structures, DNA-binding studies and antioxidant activities of the Ln (III) complexes with 7-methoxychromone-3-carbaldehyde-isonicotinoyl hydrazone | |
Terazzi et al. | Silver baits for the “miraculous draught” of amphiphilic lanthanide helicates | |
Stȩpień et al. | Core-modified porphyrin incorporating a phenolate donor. Characterization of Pd (II), Ni (II), Zn (II), Cd (II), and Fe (III) complexes | |
CN115677737A (zh) | 一种有潜在抗肿瘤作用的稀土配合物及其制备方法 | |
Hartman et al. | Mapping the intricate reactivity of nanojars toward molecules of varying acidity and their conjugate bases leading to exchange of pyrazolate ligands | |
Brüning et al. | N1 and N3 Linkage Isomers of Neutral and Deprotonated Cytosine with trans‐[(CH3NH2) 2PtII] |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |